
Fulgent Genetics FLGT
$ 18.14
-0.55%
Quarterly report 2026-Q1
added 05-23-2026
Fulgent Genetics Operating Expenses 2011-2026 | FLGT
Annual Operating Expenses Fulgent Genetics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 222 M | 181 M | 300 M | 188 M | 101 M | 41.7 M | 18.8 M | 15.7 M | 13.7 M | 10.6 M | 9.52 M | 1.33 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 300 M | 1.33 M | 92 M |
Quarterly Operating Expenses Fulgent Genetics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.1 M | 50.9 M | 54.1 M | 48.1 M | - | 43.8 M | 45.4 M | 43.9 M | - | 39.6 M | 40.4 M | 43.6 M | - | 45.7 M | 52.5 M | 40.6 M | 38.7 M | 25.1 M | 18.9 M | 18.4 M | 17.3 M | 11.9 M | 6.91 M | 5.61 M | 5.16 M | 4.95 M | 4.51 M | 4.22 M | 3.93 M | 3.86 M | 3.86 M | 4.08 M | 3.81 M | 3.72 M | 2.91 M | 3.23 M | 2.73 M | 3.56 M | 1.59 M | 2.75 M | 7.52 M | 807 K | 663 K | 530 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.1 M | 530 K | 19.9 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
Agilent Technologies
A
|
1.99 B | $ 135.53 | 0.11 % | $ 41.2 B | ||
|
Celcuity
CELC
|
172 M | $ 132.88 | 1.5 % | $ 6.21 B | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
50.6 M | $ 8.53 | -23.77 % | $ 11.3 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 21.08 | -4.66 % | $ 611 M | ||
|
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
Guardant Health
GH
|
226 M | $ 129.69 | -2.65 % | $ 16.3 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
411 M | $ 22.82 | 0.53 % | $ 1.22 B | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 136.07 | -0.53 % | $ 10.7 B | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Interpace Biosciences
IDXG
|
20 M | $ 1.7 | -5.56 % | $ 7.52 M | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
3.69 B | $ 162.96 | 2.68 % | $ 25.9 B | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 99.3 | -0.32 % | $ 6.7 B | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 180.58 | 1.47 % | $ 24.3 B | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 180.71 | -0.35 % | $ 8.96 B | ||
|
NeoGenomics
NEO
|
430 M | $ 10.52 | 3.24 % | $ 1.35 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
National Research Corporation
NRC
|
38.5 M | $ 19.53 | -0.66 % | $ 437 M | ||
|
Natera
NTRA
|
258 M | $ 223.37 | 4.41 % | $ 22 B | ||
|
Medpace Holdings
MEDP
|
118 M | $ 447.11 | -0.23 % | $ 12.9 B | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
964 M | $ 3.97 | -5.92 % | $ 368 M | ||
|
Personalis
PSNL
|
44.5 M | $ 11.4 | 3.83 % | $ 1.02 B | ||
|
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 26.39 | -0.23 % | $ 25 B | ||
|
Senseonics Holdings
SENS
|
61.8 M | $ 6.79 | 1.04 % | $ 283 M | ||
|
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
181 M | - | - | $ 2.69 B | ||
|
Twist Bioscience Corporation
TWST
|
116 M | $ 66.87 | -3.13 % | $ 4 B | ||
|
Biomerica
BMRA
|
5.64 M | $ 2.39 | -1.74 % | $ 5.49 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 260.06 | -0.75 % | $ 21.6 B | ||
|
Thermo Fisher Scientific
TMO
|
7.15 B | $ 492.51 | 1.09 % | $ 186 B | ||
|
Trinity Biotech plc
TRIB
|
28.3 M | $ 0.7 | -0.16 % | $ 251 M | ||
|
Motus GI Holdings
MOTS
|
19.1 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 8.97 | -3.55 % | $ 1.95 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 194.9 | -0.72 % | $ 21.6 B | ||
|
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M |